Clinical Trials for Pituitary Cancer
Clinical trials are research studies conducted in an effort to improve overall patient health and care.
Each trial involves running supervised tests to determine the effectiveness and safety of new drugs, procedures and/or devices with the aim of answering scientific questions about a disease or condition.
Risks and side-effects are also evaluated during these trials with results ranging from being unpleasant, with side effects such as headaches, to more serious or even life-threatening risks.
A clinical trial may be separated into phases, or steps, with each step designed to answer a separate research question. This maybe reflected in the trial name.
A brief description of each phase:
- Phase I: Usually designed to evaluate safety, determine a safe dosage range, and identify side effects on a small group of patients.
- Phase II: If Phase I is successful, the trial is then repeated with a larger group to further evaluate its effect and safety.
- Phase III: Trials are conducted on an ever larger group and are compared with the best current treatment while gathering more information on effect and safety.
- Phase IV: These studies monitor long-term side effects after the treatment has been marketed.
Clinical Trials data for Pituitary Cancer is grouped into the following categories:-
The format for each of the following is:
- The name of the trial,
- followed by whether the trial is recruiting patients,
- The trial may not have started and not yet recruiting, or the trial may have started and do not need any more recruitements, or the trial may be completed.
- Note**: Please follow the link to determine the current trial status.
- followed by a list of drug/s, if any, used in the trial
ClinicalTrials.gov has listed the following trials for Pituitary Cancer:
- Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy - This study is currently recruiting patients (Current: 23 Nov 2006) - antineoplaston A10,antineoplaston AS2-1
- Evaluation of Patients With Thyroid Disorders - This study is currently recruiting patients (Current: 23 Nov 2006)
- Evaluation of Factors in Human Brain Tumors - This study has been completed (Current: 23 Nov 2006)
- Genetic Investigation of Pediatric Tumors of the Pituitary Gland - This study is currently recruiting patients (Current: 23 Nov 2006)
- Sandostatin LAR Depot Vs. Surgery for Treating Acromegaly - This study has been completed (Current: 23 Nov 2006)
- The Treatment and Natural History of Acromegaly - This study is currently recruiting patients (Current: 23 Nov 2006)
- Penclomedine in Treating Patients With Solid Tumors or Lymphoma - This study has been completed (Current: 23 Nov 2006) - penclomedine
- Decitabine in Treating Patients With Melanoma or Other Advanced Cancer - This study has been completed (Current: 23 Nov 2006) - decitabine
- Combination Chemotherapy in Treating Patients With Advanced Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - fluorouracil,leucovorin calcium,topotecan
- Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - interferon alfa,interleukin-12
- Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors - This study has been completed (Current: 23 Nov 2006) - irinotecan,LY231514
- Combination Chemotherapy in Treating Patients With Advanced Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - fluorouracil,leucovorin calcium,SCH 66336
- Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - amifostine,carboplatin,cyclophosphamide,sargramostim
- Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - octreotide,yttrium Y 90 SMT 487
- Screening Patients With Central Nervous System Tumors for Participation in National Cancer Institute Clinical Trials - This study is currently recruiting patients (Current: 23 Nov 2006)
- Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders - This study is currently recruiting patients (Current: 23 Nov 2006)
- Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas - This study is no longer recruiting patients (Current: 23 Nov 2006) - L-778,123,L-778,123/paclitaxel,paclitaxel
- Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - indium In 111 pentetreotide
- Antineoplaston Therapy in Treating Patients With Brain Tumors - This study is currently recruiting patients (Current: 23 Nov 2006) - antineoplaston A10,antineoplaston AS2-1
- Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities - This study is currently recruiting patients (Current: 23 Nov 2006) - TRH (Thyrotropin Releasing Hormone)
- Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women - This study is no longer recruiting patients (Current: 23 Nov 2006) - Genotropin
- MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma - This study is no longer recruiting patients (Current: 23 Nov 2006) - MS-275
The format for each of the following is:
- The drug,
- followed by the name of the trial,
- followed by whether the trial is recruiting patients,
- The trial may not have started and not yet recruiting, or the trial may have started and do not need any more recruitements, or the trial may be completed.
- Note**: Please follow the link to determine the current trial status.
ClinicalTrials.gov has listed the following drugs in trials for Pituitary Cancer:
The trial data on this page has been sourced from
